Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial

Meletios A. DimopoulosUniversity of Athens School of Medicine, Alexandra Hospital, Athens, GreeceCorrespondence[email protected]

Antonio PalumboUniversity of Turin, Turin, Italy

Roman HajekFaculty Hospital FN, Brno and University of Ostrava School of Medicine, Ostrava, Czech Republic

Martin KropffUniversity of Münster, Münster, Germany

Maria Teresa PetrucciSapienza University of Rome, Rome, Italy

Philip LewisCelgene GmbH, Munich, Germany

Stefanie MillarICON Clinical Research, San Francisco, CA, USA

Jingshan ZhangCelgene Corporation, Summit, NJ, USA

Jay MeiCelgene Corporation, Summit, NJ, USA

Michel DelforgeUniversity Hospital Leuven, Leuven, Belgium

Your download is now in progress and you may close this window